Търсене на изпитвания

AI · cancer

Намерени 1,748 изпитвания за "cancer" Стр. 37 от 88

Набира участници

Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle

Bladder Cancer

The goal of this observational, in vitro study is to evaluate the effects of drugs that modulate the endocannabinoid system on spontaneous and neuronally induced contractility of the human detrusor. The study will include adult patients undergoing elective radical cystectomy for bladder cancer. The main questions it aims to answer are whether modulation of endocannabinoid receptors, enzymes involved in endocannabinoid synthesis and degradation, and endocannabinoid transport mechanisms alters basal detrusor contractility and modifies excitatory motor responses induced by neuronal activation. Participants undergoing radical cystectomy will provide written informed consent for the collection of a small sample of macroscopically healthy bladder tissue from the surgical specimen. Detrusor muscle strips will be prepared and studied in vitro using organ bath techniques. Contractile activity will be recorded under baseline conditions and after electrical field stimulation, as well as following exposure to pharmacological modulators of the endocannabinoid system. Demographic, clinical, and pathological data will also be collected for descriptive analysis.

Начало: 12.11.2025 Край: 01.05.2028 Възраст: от 18 г.

Italy Fondazione Policlinico Universitario Agostino Gemelli I NCT07545694

Набира участници

A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer

Ovarian Cancer

Evaluation Compared with traditional NACT, whether PIPAC can increase the incidence of CRS3 determines the rationality of choosing PIPAC.

Начало: 10.11.2025 Край: 10.11.2027 Възраст: 18–70 г.

China tongweihua NCT07544030

Набира участници Фаза 2

AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

Colorectal Cancer Liver Metastases (CRLM)

This is a prospective, randomized controlled, single-center phase II clinical study. It aims to compare the efficacy of AK104 plus radiotherapy combined with standard therapy versus standard therapy as first-line treatment for liver metastases from metastatic colorectal cancer.

Начало: 04.11.2025 Край: 01.11.2028 Възраст: от 18 г.

China Fudan University NCT07544784

Набира участници Фаза 1/2

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

Colorectal Cancer (Diagnosis) Colorectal Cancer Metastatic Colorectal Cancer (CRC) Immunotherapy

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg/kg IV infusion Q3W, in participants with pMMR/non-MSI-H colorectal cancer (CRC). It will also determine the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) of ABT-301. Participants will receive ABT-301 administered once daily (QD ±3 hours) or twice daily (Q12H ±3 hours, at least 9 hours apart) with water in 21-day treatment cycles. Tislelizumab 200 mg IV and bevacizumab 7.5 mg/kg IV Q3W will be given in both parts of the study.

Начало: 01.11.2025 Край: 01.07.2028 Възраст: от 18 г. Лечение

Australia, Taiwan Anbogen Therapeutics, Inc. NCT07244705

Набира участници Фаза 3

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Non-small Cell Lung Cancer (NSCLC)

TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

Начало: 31.10.2025 Край: 29.01.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +16 AstraZeneca NCT07291037

Набира участници Фаза 3

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Breast Neoplasms

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatments the participants actually receive. Participants will receive either the trial drug with chemotherapy or placebo (which looks like the trial drug but does not have any drug in it) with chemotherapy.

Начало: 30.10.2025 Край: 01.09.2030 Възраст: от 18 г. Лечение

Australia, Belgium, China +9 BioNTech SE NCT07173751

Набира участници

Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial

Hematopoietic and Lymphatic System Neoplasm

This clinical trial evaluates the impact of patient navigation and the Planning Advance Care Together (PACT) website, either alone or in combination with one another, on advanced care planning (ACP) in patients with blood cancers who received a hematopoietic cell transplant (HCT). Engagement in ACP, including having goals of care conversations, improves quality of care at the end of life and supporting this should be included in all cancer survivorship care. Patient navigation is a healthcare service that is designed to guide a patient through the healthcare system and reduce barriers to timely screening follow-up, diagnosis, treatment, and supportive care. PACT is a web-based tool that provides information about ACP, assistance with documents for advanced directives, a supportive network and a forum for discussions about ACP. Patients who engage in ACP are more likely to have higher quality of life at the end of life, receive the care they want, die where they prefer, utilize hospice effectively, and are less likely to receive futile, aggressive care at the end of life. For HCT survivors at ongoing risk of death and other disease-related complications, having a plan in place for care they want is critical. Patient navigation and/or the PACT website may improve ACP, including completion of advance care directives and goals of care conversations, in patients with blood cancers who received an HCT.

Начало: 21.10.2025 Край: 31.07.2026 Възраст: от 18 г.

United States Fred Hutchinson Cancer Center NCT07052630

Набира участници

The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer

Stomach Cancer Chemotherapy-induced Nausea and Vomiting Fatigue

In this study, we will observe the effects of the Stress Ball.

Начало: 15.10.2025 Край: 24.05.2026 Възраст: 18–80 г.

Turkey (Türkiye) Yuzuncu Yil University NCT07540169

Набира участници

Wearable Technology and Machine Learning for Early Detection and Risk Assessment of Unacceptable Toxicities in a Paediatric Oncology Cohort

Cancer Infection Digital Health Wearable Devices

Data collection study to establish a predictive model of infection observed during childhood cancer therapy using data captured by wearable technology.

Начало: 15.10.2025 Край: 01.12.2027 Възраст: 5–18 г.

Australia Murdoch Childrens Research Institute NCT07030998

Набира участници Фаза 1/2

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Small-cell Lung Cancer Neuroendocrine Carcinomas Solid Tumor Show to Express DLL3

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Начало: 14.10.2025 Край: 01.05.2029 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +4 IDEAYA Biosciences NCT07174583

Набира участници Фаза 1/2

Phase I/II Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age Related Macular Degeneration

Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-related Macular Degeneration (nAMD). PRL3-zumab will be administered Intravenously in 2-week interval for 3 doses. Normal saline (0.9% Sodium Chloride w/v) will be used in placebo treatment. The study will consist of 3 arms. Arm-1: PRL3-zumab 3mg/kg intravenously in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-2: PRL3-zumab 6mg/kg intravenously in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-3: Placebo (normal saline 0.9% sodium chloride w/v) intravenously in 2 week interval followed by 20 weeks of monitoring (n=3) Initial 3 arms will be conducted on patients who failed Standard-of-Care (SOC) therapy. Response assessment will be done at every 4 weeks from last dose of treatment till 24-week. Randomization: Randomization will be done in 2:2:1 manner on PRL3-zumab (group 1), 3mg/kg (n=6); PRL3-zumab (group 2), 6mg/kg (n=6); and placebo group (group 3) (n=3). Randomization can be achieved using random number table which will be prepared before the commencement of clinical trial. The allocation of participants will be done by Investigator and will be concealed from the participants. Blinding: Single blinding will be done for this trial in which all participants are unaware of their treatment assignment. No blinding will be done on Investigator. Primary Endpoints: 1. Safety: • Adverse Events: Frequency and severity of adverse events throughout the primary outcome assessment period. 2. RP2D: • This study will confirm RP2D established from NUH Phase I Clinical Trial in Cancer patients (MC/03/0616). 3. Efficacy: * Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by the ETDRS Letter Score. Change in BCVA letter gain of 0-4. * Change From Baseline in Central Subfield Retinal Thickness (CST). \[Assessment Time Frame: 4 weekly through 24 weeks\] Secondary endpoints: * Change in visual Acuity (Best Corrected Visual Acuity) of 5 or more letters. * Proportion of patients gaining ≥15, ≥10, ≥5, or ≥0 ETDRS letters in BCVA from baseline over time * Proportion of patients avoiding a loss of ≥15, ≥10, or ≥5 ETDRS letters in BCVA from baseline over time * Proportion of patients with absence of intraretinal fluid * Proportion of patients with absence of subretinal fluid \[Assessment Time Frame: 4 weekly through 24 weeks\] Criteria for additional Therapy: Once the treatment is stopped after the third dose, patients from all groups are eligible for additional therapy as open-label treatment if there is recurrence of disease activity, as defined by presence of any of the following criteria: 1. Decrease of ≥5 letters in BCVA compared with average BCVA value over the previous two scheduled visits, owing to nAMD disease activity (as determined by the investigator). 2. Increase of \>50 µm in OCT-measured CST compared with the average CST value over the previous two scheduled visits. 3. Recurrence of intra-retinal or sub-retinal fluid (if resolved previously) 4. New macular hemorrhage Patients in the placebo group will be given PRL3-zumab (6mg/kg) if they fulfil the criteria for additional therapy. Additional therapy will be continued in subsequent monitoring visit until the progression of disease, or end of the trial. If patients show clinical benefit from the treatment, additional doses could be given based on investigators' judgment. Criteria for progression of disease: 1. BCVA decreases by 15 letters or more from best recorded BCVA because of nAMD disease activity. 2. an increase in OCT central retinal thickness 150 µm or more from lowest recorded measurement after 2 consecutive additional therapy occurring 1 month apart.

Начало: 11.10.2025 Край: 07.07.2027 Възраст: от 18 г.

Singapore Intra-IMMUSG Pte Ltd NCT07547228

Набира участници Фаза 1

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.

Начало: 07.10.2025 Край: 30.03.2030 Възраст: от 18 г. Лечение

Australia, Switzerland, United States Amgen NCT07140900

Набира участници Фаза 2/3

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Cachexia Metastatic Pancreatic Ductal Adenocarcinoma

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.

Начало: 03.10.2025 Край: 10.12.2029 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +8 Pfizer NCT06989437

Набира участници Фаза 1

A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

Metastatic Melanoma

This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.

Начало: 01.10.2025 Край: 01.07.2027 Възраст: от 18 г. Лечение

Australia Adze Biotechnology Australia Pty Ltd NCT07086105

Набира участници Ранна Фаза 1

Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol

Healthy

This is a Phase 0 interventional, non-therapeutic study investigating the biodistribution and safety of \[18F\]-fluoromannitol as a radiotracer (a substance used to help detect disease or infection) in Positron Emission Tomography (PET) scans. The primary objective of this study is to generate safety data in healthy adult human volunteers. In the future, this tracer may help to determine if a medical problem is infectious in people who have Sickle Cell Disease, cancer or other conditions that impact the immune system, or with people who have joint implants. Primary Objective \- Generate safety data, biodistribution and perform human organ dosimetry for \[18F\]- fluoromannitol as a novel PET tracer. Participants will be recruited primarily from St. Jude Children's Research Hospital employees and SJLIFE participants, and from the broader Memphis community if needed.

Начало: 17.09.2025 Край: 01.05.2027 Възраст: 18–75 г.

United States St. Jude Children's Research Hospital NCT07110519

Набира участници Фаза 3

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

Esophageal Cancer Chemoradiotherapy

Definitive chemoradiotherapy (CRT) is the standard treatment for locally advanced unresectable esophageal cancer, but its efficacy remains unsatisfactory. More importantly, there is a lack of effective consolidation treatment after CRT, resulting in a high recurrence rate. Our previous prospective phase II trial (EC-CRT-001) demonstrated that the addition of toripalimab to definitive CRT improved the complete response rate in patients with locally advanced esophageal squamous cell carcinoma (ESCC), showing potential for enhanced long-term survival with a manageable safety profile. Nevertheless, the risk of recurrence requires further reduction. Metronomic capecitabine chemotherapy can modulate the tumor immune microenvironment and may synergize with PD-1 antibodies to enhance antitumor efficacy, potentially further prolonging survival in ESCC. Based on current research advances and our preliminary findings, this randomized, controlled, multicenter, phase III clinical trial aims to evaluate the efficacy and safety of toripalimab combined with capecitabine as maintenance therapy for patients with locally advanced ESCC who have not progressed after definitive CRT.

Начало: 10.09.2025 Край: 31.05.2030 Възраст: 18–75 г.

China Sun Yat-sen University NCT07177794

Набира участници

Digital Telecytology for Triage of HPV-Positive Women in Cameroon

Human Papillomavirus Infection Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Cervical Cancer Screening Methods

This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyping-based algorithm, including immediate treatment, telecytology triage, or follow-up. Histological assessment serves as the reference standard for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Secondary objectives include evaluation of AI-assisted telecytology and visual inspection with acetic acid (VIA), as well as the acceptability of screening and treatment strategies among women and healthcare providers. The study aims to generate evidence to support scalable, WHO-recommended test-triage-treat approaches in low-resource settings

Начало: 08.09.2025 Край: 08.09.2027 Възраст: 25–50 г.

Cameroon University Hospital, Geneva NCT07550010

Набира участници

Mechanical Bowel Preparation in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis

Colon Cancer

This study is a randomized controlled trial conducted at University Medical Center Ho Chi Minh City to evaluate the role of mechanical bowel preparation (MBP) in patients undergoing laparoscopic right hemicolectomy with totally intracorporeal anastomosis for colon cancer. Mechanical bowel preparation is commonly used before colorectal surgery to reduce bowel contents and potentially decrease the risk of postoperative infections. However, its benefit remains controversial, particularly in intracorporeal anastomosis, where intra-abdominal contamination may influence surgical outcomes. In this study, eligible patients will be randomly assigned to one of two groups: with or without mechanical bowel preparation before surgery. The study aims to compare intraoperative events, postoperative complications, and recovery outcomes between the two groups. The primary outcome is the rate of surgical site infection (SSI) within 30 days after surgery. Secondary outcomes include intraoperative fecal contamination, anastomotic leakage, postoperative ileus, operative time, and recovery parameters such as time to first bowel movement and length of hospital stay. The findings of this study are expected to clarify the role of mechanical bowel preparation in reducing postoperative infections and improving surgical outcomes in patients undergoing laparoscopic right hemicolectomy.

Начало: 01.09.2025 Край: 31.10.2027 Възраст: от 18 г.

Vietnam University Medical Center Ho Chi Minh City (UMC) NCT07546565

Набира участници Фаза 1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Renal Cell Carcinoma Urothelial Carcinoma Castration-resistant Prostate Cancer

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Начало: 27.08.2025 Край: 01.02.2029 Възраст: от 18 г.

United States Deciphera Pharmaceuticals, LLC NCT06966024

Набира участници Фаза 1

3D1015 Injection for Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer, mCRPC

This open-label clinical study investigates 3D1015 Injection (Lu 177-PSMA-3D1015) in adult males with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Participants will receive intravenous infusions of 3D1015, with treatment regimens dynamically individualized to optimize patient safety and outcomes. The primary objectives are to assess the safety, tolerability, and dosimetry of the injection. Secondary objectives include evaluating preliminary anti-tumor efficacy and exploring the optimal dosing regimen.

Начало: 27.08.2025 Край: 31.12.2027 Възраст: от 18 г.

China Chunjing Yu NCT07537010

1 … 35 36 37 38 39 … 88